INTRODUCTION
Non-tuberculous mycobacteria (NTM) infections are being increasingly reported worldwide, with Mycobacterium avium complex, Mycobacterium kansasii, Mycobacterium abscessus and Mycobacterium fortuitum being the most frequently clinically significant NTM isolated (Johnson & Odell, 2014) . This is a matter of serious concern to healthcare professionals as the two cornerstones of infection control, i.e. timely diagnosis and potent bactericidal antimicrobials, are lacking to a great extent for NTM (Brown-Elliot et al., 2012) . This is mirrored in delays in diagnosis and the long treatment regimens for most NTM infections with sub-to-moderate efficacy of most drug regimens, leading to high mortality.
The sequencing of the M. tuberculosis genome in 1998 opened up molecular avenues for tuberculosis (TB) drug discovery and development that is reflected in the current TB drug pipeline (Cole et al., 1998) . Whole-genome information on type strains of NTM is lacking so far, but this is changing rapidly as evidenced by increasing reports of whole-genome sequences being available (Bryant et al., 2013; Davidson et al., 2014; Shallom et al., 2013; Tettelin et al., 2014) . NTM share limited physiological characteristics with M. tuberculosis, with significant differences in generation time and metabolic capabilities. The fact that most of the drug target and molecular resistance information comes from studies based on M. tuberculosis is disconcerting, although some recent gains have been made on understanding resistance mechanisms in NTM (Nash et al., 2009) . Additionally, the paucity of novel drugs against NTM is exacerbated by the fact that most NTM exhibit varying degrees of intrinsic/ inducible resistance to a large number of antimicrobials utilized against them, with M. abscessus being one of the most drug-resistant mycobacteria (Griffith, 2011) .
One of the most important prerequisites for drug discovery and development is the availability of animal models mimicking human disease conditions. Although a number of animal models are available for TB, very few of these are available for NTM, with a few exceptions, thus hampering preclinical in vivo testing . All the foregoing issues an ominous challenge to the drug discovery community.
The current treatment of NTM has been standardized to a great extent based upon the recommendations set forth in the guidelines jointly issued by the American Thoracic Society and Infectious Disease Society of America in 2007 (Griffith et al., 2007) . The antimicrobial armamentarium against rapidly growing NTM primarily consists of macrolides, aminoglycosides, fluoroquinolones, oxazolidinones, tigecycline, carbapenems and cephalosporins, whilst for the slow-growing NTM species such as M. avium and Mycobacterium intracellulare, rifampicin, macrolides, ethambutol and amikacin are the front-line agents. All these therapies have varying efficacies in vivo (Maurer et al., 2014) .
The purpose of this review is to underscore the paucity of available drugs active against NTM amongst the newest classes being discovered and developed for TB, and highlight the need for a concerted drug discovery pipeline targeting NTM. Some other drugs, including linezolid, telithromycin, moxifloxacin and clofazimine, are of great interest for use as anti-NTM agents, but have already been extensively reviewed elsewhere (Brown-Elliot et al., 2012) . Towards this end, we examine the newer drugs which are in various stages of clinical and preclinical development for M. tuberculosis infection, and characterize the activity of each for NTM where information is publicly available. The drugs discussed are classified according to their mode of action as depicted in Fig. 1 .
DRUGS TARGETING DNA GYRASE DC-159a
DC-159a is a new-generation 8-methoxyfluoroquinolone developed by Daiichi Sankyo (Japan). Similar to other members of the fluoroquinolone group, it also inhibits the supercoiling action of DNA gyrase. It shows excellent activity against M. tuberculosis, especially against quinolone-resistant MDR-TB and M. kansasii; however, it loses potency against other NTM and in vivo efficacy data against NTM are not available (Disratthakit & Doi, 2010) . MICs were determined by the standard agar dilution method. The structure of DC-159a is represented in Fig. 2 and its microbiological properties are listed in Table 1 .
DRUGS TARGETING CELL WALL BIOSYNTHESIS Delamanid
Delamanid is a nitroimidazo-oxazole designed from the lead parent compound CGI 17341 and exhibits its antimycobacterial activity by inhibiting the synthesis of mycolic acid, a component of the cell wall of mycobacteria. It gained regulatory approval for treatment of MDR-TB in 2012/2013. Delamanid demonstrates potent in vitro activity against M. tuberculosis and M. kansasii. However, it proved to be ineffective against M. avium and M. intracellulare; in vivo efficacy data are lacking against NTM (Doi & Disratthakit, 2006) . MICs were determined by the standard agar dilution method. The structure of delamanid is represented in Fig. 2 and its microbiological properties are listed in Table 2 .
Pretomanid (PA-824)
Pretomanid is a pro-drug bicyclic nitroimidazole that has been developed to treat replicating, non-replicating and hypoxic drug-sensitive and drug-resistant TB. A microarray study showed that PA-824 inhibits cell wall formation by blocking mycolic acid biosynthesis and respiratory poisoning (Manjunatha et al., 2009 ). The drug is active against M. tuberculosis complex and M. kansasii, although no such activity was observed against M. avium, Mycobacterium chelonae and M. fortuitum, presumably since they lack the activation gene (Doi & Disratthakit, 2006; Manjunatha et al., 2009; Stover et al., 2000) . MICs were determined by the standard agar dilution method. The structure of PA-824 is represented in Fig. 2 and its microbiological properties are listed in Table 3 .
CPZEN-45
CPZEN-45 is a semi-synthetic nucleoside antibiotic developed by BIKAKEN (Japan) that targets TagO, which is 
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involved in the synthesis of the mycolylarabinogalactan portion of the cell wall. Mutation in TagO leads to CPZEN-45 resistance (Ishizaki et al., 2013) . MICs were determined by the serial agar dilution method. The structure of CPZEN-45 is represented in Fig. 2 and its microbiological properties are listed in Table 4 .
SQ-109 and SQ-73
SQ-109 is a novel ethylenediamine analogue of ethambutol developed by Sequella (USA) and is currently in phase II clinical trials (Sacksteder et al., 2012) . SQ-109 exhibits potent bactericidal activity against ethambutol-resistant organisms, indicating that its mechanism of action is (Tahlan et al., 2012) . As ethambutol possesses at best modest efficacy against most rapidly growing NTM, SQ-109 loses most of its potency against the NTM tested in comparison with M. tuberculosis.
SQ-73, another member of the diamine family, demonstrated better activity in macrophages (Protopopova et al., 2005) . No MIC data or in vivo efficacy data for SQ-73 against NTM are available. The microbiological properties of SQ-109 are listed in Table 5 and its structure, along with SQ-73, is represented in Fig. 2 .
SQ-641
SQ-641 is a potent anti-TB candidate identified from a library of w7000 analogues of capuramycin created by Daiichi-Sankyo (Japan), and targets translocase I (TL1) with potent bactericidal activity against mycobacteria (Hotoda et al., 2003; Koga et al., 2004) . Translocase I is an essential enzyme for the biosynthesis of the bacterial cell wall. SQ-641 was shown to be bactericidal against different NTMs tested, with a minimum bactericidal concentration/MIC ratio ranging from 1 to 8 and killed all mycobacteria faster than positive control drugs for each strain, including clarithromycin, rifampicin, amikacin and streptomycin. In chequerboard titrations, SQ-641 was synergistic with ethambutol against both M. avium complex and Mycobacterium smegmatis, and was synergistic with streptomycin and rifabutin against M. abscessus (Dubuisson et al., 2010) . Standard broth microdilution assay, as well as the agar dilution method, were performed to determine MICs for all strains. However, in vivo efficacy data against NTM are lacking for SQ-641. The structure of SQ-641 is represented in Fig. 2 and its microbiological properties are listed in Table 6 .
Dinitrobenzamide (DNB)
The enzyme decaprenylphosphoryl-b-D-ribose 29-epimerase (DprE1) is a preferred drug target involved in arabinogalactan and lipoarabinomannan synthesis. Christophe et al. ). There are two DNB derivatives: DNB1 and DNB2. Structureactivity relationship studies show that the nitro groups are responsible for exhibiting potent antimycobacterial activity. MICs were determined by the broth microdilution assay. As expected, DNB loses potency against M. smegmatis; in vitro or in vivo data against other NTM are not available. The structure of DNB is represented in Fig. 2 and its microbiological properties are listed in Table 7 . 
BTZ043/PBTZ169
BTZ043 is potent suicide inhibitor of DprE1, an essential flavoenzyme involved in arabinan biosynthesis (Makarov et al., 2009; Trefzer et al., 2012) . BTZ043 is very near to phase I clinical trials. In an effort to further increase the potency of the BTZ class, PBTZ has been synthesized by introducing a piperazine group into the BTZ scaffold resulting in PBTZ169.
As can be seen from Table 8 , they both lose potency against most NTM tested, except M. smegmatis and Mycobacterium marinum. MICs were determined by the resazurin reduction microplate assay. There are no in vivo efficacy data available against NTMs for either BTZ043 or PBTZ169. The structures of BTZ043/PBTZ169 are represented in Fig. 2 and their microbiological properties are listed in Table 8 .
Indolcarboxamides
Indolcarboxamides (NITD-304 and NITD-349) were discovered by Novartis Institute for Tropical Diseases (Singapore) and demonstrated potency against both slowgrowing (M. tuberculosis and Mycobacterium bovis BCG) and fast-growing (M. smegmatis) mycobacterial species, indicating that the molecular target of these compounds may be restricted to mycobacteria, i.e. trehalose monomycolate transporter MmpL3, which is essential for mycobacterial cell wall biosynthesis, as revealed through mechanistic studies (Rao et al., 2013) . Two lead compounds from this group, NITD-304 and NITD-349, showed potency against MDR M. tuberculosis clinical isolates. MICs were determined by the broth microdilution method. Their oral administration was efficacious in reducing infection in acute and chronic mouse models of TB infection. The structures of NITD-304/NITD-349 are represented in Fig. 2 and their microbiological properties are listed in Table 9 .
DRUGS TARGETING PROTEIN METABOLISM Tigecycline
Tigecycline is the first in the glycylcycline class of protein synthesis inhibitors that have been approved by the US food and Drug Administration since 2005 and possess very potent activity against NTM (Stein & Craig, 2006; Wallace et al., 2002) . Tigecycline was designed to circumvent the major mechanisms of bacterial resistance to tetracyclines, including those observed in rapidly growing mycobacteria pathogens.
In a comparative in vitro study that included 72 isolates of rapidly growing mycobacteria, tigecycline MICs were j1 mg l 21 for all tested tetracycline-susceptible and tetracycline-resistant isolates of M. abscessus, M. chelonae and M. fortuitum. In addition, tigecycline was approximately four dilutions more active than tetracycline, doxycycline and minocycline against tetracycline-susceptible organisms (Broda et al., 2013) . Susceptibility testing was performed by the broth microdilution method. The structure of tigecycline is represented in Fig. 2 and its microbiological properties are listed in Table 10 .
Tigecycline is the only antimicrobial active against NTM for which any clinical trial data are available. It was evaluated in two trials: Study 205 and 310. Study 205 (ClinicalTrials.gov ID; NCT00600600) was a phase II, open-label, non-comparative, single-centre, investigator-initiated study conducted at the University of Texas Health Northeast that investigated the efficacy, safety and tolerability of tigecycline in patients with rapidly growing mycobacterial The results of the above-mentioned trials have been released recently (Wallace et al., 2014) . In patients with M. abscessus and M. chelonae infections, including those suffering from cystic fibrosis, i60 % improvement was demonstrated when tigecycline was given for i1 month as part of a multidrug regimen, with mild nausea and vomiting as the main side effects. This result was even more intriguing bearing in mind that *90 % of the patients had a history of prior drug therapy failure (Wallace et al., 2014) .
TP-271
TP-271 is a fully synthetic novel fluorocycline antibiotic related to tetracycline, discovered and developed by Tetraphase Pharmaceuticals (USA). It possess potent activity against NTM and has been reported to inhibit in vitro transcription/translation with around sevenfold greater potency than tetracycline (Cynamon et al., 2012; Starosta et al., 2010) . MICs were determined by the microbroth dilution assay. However, no in vivo efficacy data are available for TP-271 against NTM. The structure of TP-271 is represented in Fig. 2 and its microbiological properties are listed in Table 11 .
DRUGS TARGETING ENERGY-GENERATION PATHWAYS Bedaquiline
Bedaquiline is the latest drug indicated for the treatment of MDR-TB, and received US Food and Drug Administration approval in 2011. It targets the ATP synthase of mycobacteria and was discovered and developed by Johnson & Johnson (Huitric et al., 2007; Koul et al., 2007) . Although bedaquiline has excellent in vitro activity against M. avium and M. abscessus, it lacks bactericidal activity in vitro and in vivo (Lerat et al., 2014; Lounis et al., 2009) . Susceptibility testing was done by the agar dilution method. The structure of bedaquiline is represented in Fig. 2 and its microbiological properties are listed in Table 12 .
CURRENT CLINICAL TRIAL STATUS
All the above-mentioned drugs are in various phases of clinical trials against M. tuberculosis, not explicitly against NTM. Drugs including DC-159a, SQ-641, CPZEN-45, BTZ043, PBTZ169, DNB and indolcarboxamides are in the preclinical phase against M. tuberculosis, whereas SQ-109 and SQ-73 are in phase II trials. The phase III trial field is more crowded, with delamanid, bedaquiline and PA-824 in phase III against drugsensitive and drug-resistant TB. Additionally, tigecycline is in phase III for treating ventilator-associated pneumonia.
To summarize, many of the drugs being developed for treating TB do not exhibit any antimicrobial activity against NTM. Even more concerning is the lack of animal efficacy data as well as any clinical trial data pertaining to NTM for most of the drugs. Even for the available drugs, there is a near universal lack of cidality which makes clinical case management much more complicated.
One of the critical components that is lacking for most NTM infections is the availability of standardized animal models which mimic human disease and pathology. This is, however, changing with the availability of the granulocyte macrophage colony-stimulating factor mouse model developed for M. abscessus and a variety of other animal models under development Ordway & Orme, 2011) . We call for the drug discovery community to consider dedicated programmes for discovering drugs against NTM and that concerted action be taken in this regard.
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